This survey is intended for Callen-Lorde patients who are currently taking daily PrEP, to gauge interest in an injectable PrEP option called Cabotegravir (Cahbo-TE-gra-veer). Cabotegravir is an injectable medication used to treat HIV that will soon be offered as the first long-acting therapy for HIV prevention.

Please note this survey is Anonymous and no personally identifying information will be collected.